# A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants

> **NCT05003089** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 51 (actual)

## Conditions studied

- Immune Mediated Inflammatory Diseases

## Interventions

- **DRUG:** BAY1834845
- **DRUG:** BAY1830839
- **DRUG:** Prednisolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05003089
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-28
- **Primary completion:** 2021-12-16
- **Final completion:** 2022-01-20
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2022-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05003089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05003089, "A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05003089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*